FORMA CRISTALINA DEL COMPUESTO 3-{[5-(ACETIDIN-1-ILCARBONIL)PIRACIN-2-IL]OXI}-5-[(1-METILETIL)OXI]-N-1H-PIRAZOL-3-ILBENZAMIDA; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHA FORMA; Y USO PARA EL TRATAMIENTO DE LA DIABETE

摘要

A novel crystalline form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1-methylethyl)oxy]-N-1H-pyrazol-3-ylbenzamide is described in the specification. This compound is a glucokinase (GLK or GK) activator and useful as a pharmaceutical agent in the treatment or prevention of a disease or medical condition mediated through GLK, leading to a decreased glucose threshold for insulin secretion. Processes for the manufacture of the crystalline form, pharmaceutical compositions comprising the crystalline form and the use of the crystalline form in medical treatment are also described.